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Background: Aortic stenosis (AS) is the most common valve disease in the adult population and its 
prevalence increases with age. Unfortunately, older age and comorbidities significantly increase mortality, 
operative risk and worsen prognosis. In recent years, sutureless bioprosthesis [sutureless-aortic valve 
replacement (SU-AVR)] has become an alternative to standard AVR or TAVI in high-risk patients. Compared 
to standard AVR, the advantages of SU-AVR include shorter valve implantation, shorter aortic cross clamp 
(ACC) and cardiopulmonary bypass (CPB) times and higher valve EOA with more favorable hemodynamic 
parameters. Good early clinical and hemodynamic outcomes have been reported in several studies. However, 
although early SU-AVR results reported in the literature are encouraging, there are few results of long term 
follow-up. The aim of this study is to present long term echocardiographic hemodynamic outcomes of the 
Enable sutureless bioprosthesis.
Methods: The first human implantation of the Enable sutureless bioprosthesis was performed on the 13th 
January, 2005 by the authors of this manuscript. From that time until July 2008, 25 patients underwent 
isolated SU-AVR implantation. The median preoperative logistic EuroSCORE was 1.92±0.17 [standard 
deviation (SD)] and the STS score was 2.96±2.73. Preoperatively, 65.4% of patients were in NYHA class III 
or IV, the peak/mean gradient transaortic gradient was 84.6/52.1 mmHg.
Results: After the SU-AVR procedure, the average peak/mean aortic gradients were respectively:  
12.9/7.1 mmHg at the intraoperative time; 18.1/9.5 mmHg at 3–6 months; 18.3/9.6 mmHg at 11–14 months;  
16.9/9.3 mmHg at 2 years; 15.3/8 mmHg at 3 years; 13.4/7.1 mmHg at 4 years; 16.7/8.9 mmHg at 5 years 
follow-up. Other hemodynamic echocardiographic parameters such as LVOT diameter, LVOT peak velocity, 
LVOT TVI, valve peak velocity and valve TVI were stable during the follow-up period.
Conclusions: In summary, sutureless bioprostheses are safe and effective treatments for valve stenosis with 
excellent outcomes and hemodynamic profile which remained stable during the follow-up period. The peak 
and mean gradients were 16.7 and 8.9 mmHg, respectively, over a 5-year follow-up period.
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Introduction
Aortic stenosis (AS) is the most common valve disease in 
the adult population (1). It is predicted that the incidence 
of aortic valve disease will increase due to an ageing 
population. Aortic valve replacement (AVR) remains the 
standard treatment among patients with severe AS (2). 
However, older age and comorbidities significantly increase 
the operative risk and worsen prognosis (1).
As a result, new strategic options such as transcatheter 
aortic valve implantation (TAVI) or sutureless AVR (SU-AVR) 
have emerged in elderly and high-risk patients. TAVI 
became an accepted, alternative method in selected groups 
of patients with isolated aortic valve disease. However, 
these techniques are associated with an increased number of 
complications such as stroke, arrhythmia, coronary ostium 
occlusion, paravalvular leak or vascular complications (3-5). 
It is important, during TAVI, that the native stenosed 
aortic valve is not removed. This means that the durability 
of TAVI procedure remains uncertain, especially when 
available literature on long term outcomes is limited.
Recently, sutureless bioprosthesis became an alternative 
method to standard AVR or TAVI in high-risk patients. 
Compared to standard AVR, the advantages of SU-AVR 
include shorter valve implantation, shorter aortic cross 
clamp (ACC) and cardiopulmonary bypass (CPB) times and 
higher valve EOA with beneficial hemodynamics parameters 
(6-9). In contrast to the TAVI procedure, during SU-AVR, 
the native stenosed valve is totally removed ensuring good 
valve fixation on the aortic ring. Good early clinical and 
hemodynamic outcomes have been reported in several 
studies (6,8,9). However, although early SU-AVR results 
are encouraging, there are only a few results reported in the 
literature on long term follow-up.
Aim
The aim of this study is to present clinical and hemodynamic 
long term outcomes of 3f Enable sutureless bioprosthesis.
Methods
From June 2005 to July 2008, 27 patients in our institution 
underwent isolated SU-AVR with the 3f Enable sutureless 
bioprostheses (ATS Medical, Minneapolis, MN, USA). 
Patient exclusion criteria were severe deformations of 
aortic ostium, bicuspid aortic valve, left ventricle ejection 
fraction <30%, disease of any other heart valve requiring 
surgery, pathological changes in the ascending aorta (e.g., 
significant dilatation/aneurysm), systemic connective tissue 
disease (e.g., Marfan’s syndrome), accompanying coronary 
heart disease, severe illness of any other organ (e.g., COPD, 
advanced renal failure, neoplastic disease, stroke with 
significant neurological deficiency)
The 3f Enable bioprostheis (Figure 1) is a new-generation 
sutureless prosthesis consisting of equine pericardium and a 
self-expanding nitinol frame. The valve is available in 6 sizes: 
from 19 mm up to 29 mm (in 2 mm steps). Detailed valve 
description is available in our previous publications (8,9).
Data were collected using a standardized case report 
and a retrospective analysis was performed. The study was 
approved by the Bioethics Committee at the Jagiellonian 
University in Krakow, Poland (No. 122.6120.3235.2014).
Follow-up
TTE were performed before operation, during the first 
post-operative day, at 3–6, 11–14 months and at 2, 3, 4 and 
5 years after the procedure. At each visit, hemodynamic 
parameters were assessed via TTE by two-dimensional, 
M-Mode, pulsed-wave and color-flow imaging.
Patients were followed up to 5 years post procedure for 
SAE and re-operation. One year after the procedure, one 
patient refused to continue follow-up visit. He was excluded 
from further analysis. The remaining 25 patients (92.6%) 
complete 5 years of follow-up
Statistical analysis
Descriptive statistics are presented for baseline demographic 
and clinical parameters. Continuous variables are presented 
as mean ± standard deviation (SD) and nominal variables 
are presented as frequency (%). Statistical analysis was 
performed using Statistica 10 software (StatSoft Inc., Tulsa, 
OK, USA).
Results
Patient baseline characteristics are presented in Table 1. 
Mean age was 71.9±5.2 years (range, 60–84 years) and 
68% were female. The mean Society of Thoracic Surgeons 
predicted mortality risk score was 2.96%±2.73% (range, 
1.14–15.16%). The mean logistic EuroSCORE II predict 
operative mortality risk was 1.92%±0.17% (range, 1–4.7%). 
Echocardiographic results are presented in Table 2. Before 
AVR, the average peak aortic gradient was 84.6 mmHg and 
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mean aortic gradient was 52.1 mmHg.
The mean ACC time was 56.0±18.4 min (range, 28–90 min) 
and CPB was 83.0±22.6 min (range, 40–126 min). 
After the AVR procedure, the average peak/mean aortic 
gradients were respectively: 12.9/7.1 mmHg at the 
intraoperative time; 18.1/9.5 mmHg at 3–6 months; 
18.3/9.6 mmHg at 11–14 months; 16.9/9.3 mmHg at 
2 years; 15.3/8 mmHg at 3 years; 13.4/7.1 mmHg at 4 years; 
16.7/8.9 mmHg at 5 years follow-up. A complete summary 
of peak and mean trans-prosthetic gradients are present in 
Figure 2. The EOA and EAOi were respectively: 1.87 cm2 
and 1.08 cm2/m2 at the intraoperative time; 1.74 cm2 and 
0.98 cm2/m2 at 3–6 months; 1.67 cm2 and 0.93 cm2/m2 at 
11–14 months; 1.87 cm2 and 1.01 cm2/m2 at 2 years; 1.95 cm2 
and 1.10 cm2/m2 at 3 years; 1.73 cm2 and 0.95 cm2/m2 at 
4 years; 1.57 cm2 and 0.87 cm2/m2 at 5 years (Table 2).
Early adverse event rates have been reported. There was 
one re-operation on post-operative day 4 as a consequence 
of a significant perivalvular leak caused by small implant 
displacement (8).
In 5 years of follow-up of the group, there were 
no deaths, re-operations or other SAEs including 
thromboembolic complications, endocarditis, pacemaker 
implantation or valve structure failure were observed. In 
one patient, after 1 year of follow-up, a small perivalvular 
leak was detected. However, in further TTE, no increase of 
the leak was detected, and no re-operation was required. No 
migration or dislodgement of the prosthesis has occurred 
during further follow-up.
Discussion
This study is one of the longest follow-up studies 
of sutureless bioprosthesis. Five years of follow-up 
demonstrated that the sutureless 3f Enable valve presents 
an excellent hemodynamic profile with peak and mean 
gradients of 16.7 and 8.9 mmHg respectively and acceptable 
clinical outcomes.
AVR remains the gold standard in the treatment in 
aortic valve disease. Along with the aging population comes 
a concomitant sharp rise in the incidence of aortic valve 
disease. However, older age and concomitant comorbidities 
significantly increase the risk of mortality and morbidity 
(10,11). Novel sutureless bioprostheses combine the 
advantages of both techniques: conventional AVR and 
TAVI. Recently, SU-AVR techniques are proposed as 
methods of choice in high-risk patients belonging to the 
“grey zone” between TAVI and conventional surgery 
(3,12,13). In the literature there are only a few studies that 
present mid and long term outcomes of SU-AVR.
The hemodynamic parameters of sutureless valves 
are one of their most important advantages. Sutureless 
bioprostheses present reduced mean and peak gradients, 
increased transvalvular flow and acceptable effective orifice 
area. Our report presents excellent, stable and comparable 
hemodynamic parameters during 5 years of observation. 
Compared to short term results from other studies, our results 
are better or comparable to other SU-AVR studies. Intuity 
Edwards (8.4 mmHg) (14), Perceval (9.0–12.5 mmHg) (15) 
and Trilogy bioprostheses were also implanted in the authors’ 
center (10 mmHg) (16). Similar long term results were 
report by other centers that implanted the 3f Enable (17). 
Our results were also comparable with those of conventional 
tissue valves, including procedures performed in our center 
(7,18).
The mean EOA values report in our study at each 
follow-up visit are above the recommended lower limit of 
1.2 cm2 and the EOAi mean values are also above the lower 
limit for mild/not significant (0.85 cm2/m2) prosthesis-
patient mismatch (PPM) which is consistent with other 
study results (17). Short term EOA results are comparable 
for 3f Enable, Trilogy, Edwards Intuity and slightly lower 
for Perceval at discharge (1.9 vs. 1.8 vs. 1.7 vs. 1.4 cm2), at 
3–6 months (1.7 vs. 1.9 vs. 1.7 vs. 1.5 cm2) and at 1 year 
after implantation (1.7 vs. 1.9 vs. 1.7 vs. 1.5 cm2) (14,16,19). 
Sutureless valves present excellent and stable hemodynamic 
Figure 1 ‘Enable’ valve: the lateral view: valvular tube, fixing ring, 
commissura fixation area, upper ring of the nitinol stent.
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Table 1 Patients characteristic
Preoperative characteristics Results Range/N
Female, sex 68% 17
Age 71.9±5.2 (SD) Range, 60–84
STS (%) 2.96±2.73 (SD) Range, 1.14–15.16
EUROscore 2 (%) 1.92±0.17 (SD) Range, 1–4.7
BMI (kg/m2) 28.6±4.78 (SD) Range, 16.9–36.7
Underweight BMI (<18.5) 4% 1
Normal BMI (18.5–24.9) 16% 4
Overweight BMI (25.0–29.9) 40% 10
Obese class I (30.0–34.9) 32% 8
Obese class II (35.0–39.9) 8% 2
EF (%) 56.8±2.01 (SD) Range, 45–71
Max. aortic gradient (mmHg) 84.6±23.7 (SD) Range, 20–148
Min. aortic gradient (mmHg) 52.1±16.4 (SD) Range, 9–100
Cardiac rhythm
Sinus 84.6% 22
Paroxysmal AF 3.8% 1
Chronic AF 11.5% 3
NYHA
I 3.8% 1
II 30.8% 8
III 57.7% 15
IV 7.7% 2
Comorbidities
Coronary artery disease 23.1% 6
Previous MI 3.8% 1
PCI 3.8% 1
Carotid artery disease 3.8% 1
Hypertension 76.9% 20
Lower leg inflammation 3.8% 1
Hyperlipidemia 34.6% 9
Thyroid disease 15.4% 4
Diabetes 15.4% 4
COPD 11.5% 3
Gastrointestinal ulcer 11.5% 3
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efficacy. Additionally, compared to our center’s experience 
with conventional stented biological or mechanical heart 
valves, the sutureless bioprostheses present favorable 
hemodynamic parameters (18,20). It should be mentioned 
that, in our study, EOA was calculated using individual 
echocardiographic parameters that provide a more accurate 
approach and quality in contrast to studies where the EOA 
is obtained from previously published studies or in vitro 
measurements provided by the valve manufactures (17).
The overall rate of serious adverse events observed in our 
cohort of patients was low. There were no SAEs including 
endocarditis, thromboembolic complications or pacemaker 
implantation. Of note, there was no valve structure failure. 
There was only one re-operation in peri-operative period 
because of perivalvular leak (3.7%). Of note, similar long 
term results were obtained among other centers that 
implanted the Enable valve (17). Also, SU-AVR meta-
analysis presents an acceptable rate of SAE, including 
strokes and re-operations, compared to conventional AVR, 
supporting the safety of SU-AVR in short term outcomes. 
It is interesting that there were no significant differences 
in stroke prevalence between TAVI and SU-AVR. 
However, these results were published in a small group of 
patients (3).
An increased rate of pacemaker use in SU-AVR 
was observed (6.76%) compared to conventional AVR 
(3.6%) (14,15,21). However, pacemaker use was still 
lower compared to TAVI where the need for permanent 
pacemaker implantation was significantly higher and 
observed in up to one quarter of TAVI patients (3,22). Left 
bundle branch block was present in 60% of patients after 
TAVI compare to 7.5% of SU-AVR.
It should be noted that in our study, there were no deaths 
after 5 years of observation. Meta-analysis showed that early 
mortality after sutureless bioprostheses was between 2.1% 
and 3.2% which was lower compared to the mean patients 
EuroSCORE (21,23). One year mortality rate data showed 
2.4% for Perceval (19) and 7.5% for Edwards Intuity (14). 
In SU-AVR meta-analysis, there was an acceptable rate 
of mortality from 1.4% to 2.3%, when compared to 
conventional AVR (14,15). There were no significant 
differences in in-hospital mortality after SU-AVR (0–2.6%) 
and TAVI (1.8–5.3%) (5,24). However, score-matched 
analysis resulted in 144 pairs of intermediate-risk patients 
with similar baseline characteristics in demonstrating 
significantly higher in-hospital mortality after TAVI 
compare to SU-AVR (6.9% vs. 1.4%, P=0.035) (24).
There are only a few studies in the literature that report T
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long term mortality. There are two 5 year observational 
studies of Perceval that reported higher mortality compare 
to our results with 71.3% and 85.5% survival after the 
procedure (25,26). However, our results are difficult to 
compare because of different patient selection criteria, 
baseline characteristic and operative risk compare to other 
studies. Compared to other studies, our cohort of patients 
was younger, had lower STS score and only the isolated 
AVR procedure were performed (17,19,27).
There is a perception that sutureless bioprostheses 
increase the risk of paravalular leaks. In our report, there 
was one clinically significant paravalular leak 4 days after 
the procedure that required re-operation and one patient 
presented with a small PVL without clinical consequences 
1 year after the procedure. The highest percentage of 
PVL has been reported for the Trilogy valve (6.6%). The 
incidence of PVL for 3f Edwards (2.8%), Perceval (4%) and 
Intuity (2.3%) have been similar. Of note, the presence of 
PVL after SU-AVR is significant lower compare to TAVI 
procedure. The PARTNER trial reported that a trace to 
mild PVL was observed up to 66% of patients and moderate 
to severe PVL in 12% (4,28).
Valve migration or dislocation is a severe life-threating 
complication observed in up to 8% of TAVI procedures (29). 
This complication may be also observed in the SU-
AVR procedure. Although, 3f Enable presented good 
hemodynamic and clinical outcomes, the valve was 
withdrawn from the market because of reported valve 
migration (24). However, along with the increased number 
of SU-AVR procedure, valve migration is also observed in 
other types of sutureless bioprostheses (30). In our study, no 
migration or valve dislocation was observed.
Prolonged ACC and CPB significantly increase the 
risk of postoperative mortality and morbidity after cardiac 
surgery (31). The STS database for isolated full sternotomy 
AVR reports 78 minutes for ACC and 106 minutes for 
CBP (23). Compare to conventional AVR, SU-AVR 
implantation time is shorter because of self-expanding 
bioprostheses and valve fixation in aortic root without suture. 
Therefore, SU-AVR reduces the duration of operations 
including ACC and CBP. In our report, mean ACC was 
56 min and CBP was 83 min. These results were shorter 
compare to the STS database, but relatively long compared 
to results of SU-AVR meta-analysis, where for isolated SU-
AVR ACC was 33 min and CBP was 57 min (23). This may 
be explained by the fact that our study presents the first 
clinical experience with sutureless bioprostheses, a technique 
in 2005 which was completely innovative. Of note, along with 
an increased number of procedures, times were systematically 
shortened, up to 30 minutes for ACC.
Other advantages of SU-AVR over conventional AVR are 
the latter requiring longer operations times. Implantation of 
a sutureless bioprosthesis through a ministernotomy or right 
minithoracotomy was associated with shorter ACC and 
CBP and less transfusion of packed red blood cells (5,32-36). 
According to minimally invasive procedure, sutureless 
bioprostheses might be a good therapeutic option for 
patients undergoing multiple concomitant procedures (6,37) 
Figure 2 Mean and peak gradients.
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including multiple valve-surgery (38). SU-AVR benefits 
were also observed in high risk cardiac re-operation (37,39), 
in patients with small aortic annulus (20,40), in porcelain 
aorta (41) or in calcified homograft (42,43). However, in 
our center, only isolated full sternotomy AVR procedures 
were performed. This is common for the first clinical trial 
involving new types of sutureless valves in new centers 
(17,23). During the first sutureless valve implantation in the 
world, investigators preferred isolated AVR procedure with 
full approach to aorta.
In this study, we demonstrate excellent long term 
hemodynamic outcomes after SU-AVR using 3f Enable 
bioprostheses. Five years after the procedure, the peak and 
mean gradients were 16.7 and 8.9 mmHg, respectively. 
Unfortunately, due to the lack of long term follow-up, 
comparisons of different type of sutureless bioprostheses are 
difficult.
In the authors’ opinion, SU-AVR literature is limited. 
In recent years, TAVI techniques have become popular 
in AVR surgery to the detriment of SU-AVR techniques. 
The advantages and disadvantages of SU-AVR over TAVI 
and conventional AVR should be demonstrated in large 
prospective randomized clinical trials which include 
financial analyses.
Sutureless bioprostheses are a safe and effective treatment 
for valve stenosis with excellent outcomes and hemodynamic 
profiles. The advantages of SU-AVR are that this technique 
can be used in minimally invasive surgery, when concomitant 
procedures are required and in high risk patients in the “grey 
zone” between TAVI and conventional surgery.
The limitations of this study that it was a retrospective 
study, there was a small group of patients and the study 
lacked a control group. Finally, the study focused mainly on 
hemodynamics outcomes.
Conclusions
In summary, sutureless bioprostheses are safe and effective 
treatment for valve stenosis with excellent outcomes and 
hemodynamic profiles. The peak and mean gradients were 
16.7 and 8.9 mmHg respectively after 5 years of follow-
up. However further large, randomized studies are needed 
in order to establish guidelines for SU-AVR in aortic valve 
disease.
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